Zentalis Pharmaceuticals launches underwritten public offering of common stock, pre-funded warrants

Reuters2026/08/13 20:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zentalis launched a proposed underwritten public offering of common stock.
Some investors can choose pre-funded warrants to buy common shares in lieu of stock.
Underwriters hold a 30-day option to purchase up to 15% additional shares on the same terms.
Proceeds earmarked for clinical trials, preclinical work, regulatory filings, manufacturing, companion diagnostic development, pre-commercial activities, capital spending, working capital.
TD Cowen, Guggenheim Securities, Oppenheimer are joint bookrunners.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131601PRIMZONEFULLFEED9809901) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zentalis Pharmaceuticals launches underwritten public offering of common stock, pre-funded warrants

You may also like

Crypto prices